? Biostatistics Shared Resource The Biostatistics Shared Resource (BSR) is a SJCCC managed shared resource with the overarching mission of impacting pediatric cancer through biostatistics collaboration and consulting, and through comprehensive, effective, and timely biostatistical support to Center members. BSR has a highly experienced and interactive team of biostatisticians who work collaboratively with researchers who are conducting leading edge basic science, clinical research, and population and survivorship research from the 5 SJCCC Programs. This is evidenced by the high level of collaborative publications and key scientific contributions in high-impact journals such as Journal of Clinical Oncology (n=31), Cancer (n=31), Nature Genetics (n=9), and Lancet Oncology (n=4). In addition, BSR biostatisticians are well integrated into the clinical trial teams providing statistical support throughout the life cycle of the research project from concept development through publication. During the last funding period, 85% of all SJCCC publications used the BSR and 77% (n=358/468) of all collaborative publications with a biostatistician as a co-author were associated with SJCCC programs. These included papers from all 5 of the programs: CCSP (n = 103), CBP (n = 1), DBSTP (n = 66), NBTP (n = 83), and HMP (n = 105). A total of 125 St. Jude investigators and their staff used the BSR during the index year (FY2017). Of those, 71 (57%) were SJCCC members. The BSR faculty also offer workshops, office consultations, lectures, seminars, Grand Rounds, and courses on study design, analysis methods, and software implementation to fellows, research staff, and faculty. The BSR is led by Dr. Deo Kumar Srivastava who has more than 23 years' experience in the statistical design and analysis of cancer research and cancer clinical trials. He is supported by 9 faculty biostatisticians and 13 master's-level trained staff, ensuring that BSR support is available to investigators throughout all 5 programs. During our most recent funding period, BSR has witnessed growth driven by the strengthening of the scientific programs, research in genomic characterization of pediatric cancers, and focus on complex precision medicine SJCCC investigator-initiated multisite trials. Goals for the next funding period include continuing to provide state-of-the-art statistical support to all SJCCC investigators including new investigators, and targeted recruitment of biostatisticians to strengthen expertise in personalized medicine, immunotherapy, and in expansion of high-throughput big data. Lastly, BSR will closely partner with the Information Services department in the implementation of the new software provided by the Clinical Trials Management System.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-40
Application #
9632005
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Devine, Katie A; Mertens, Ann C; Whitton, John A et al. (2018) Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). Psychooncology 27:613-619
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Hazlitt, Robert A; Min, Jaeki; Zuo, Jian (2018) Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. J Med Chem 61:5512-5524
Hoehn, Mary Ellen; Calderwood, Julie; Gannon, Edwin et al. (2018) Ocular complications in a young pediatric population following bone marrow transplantation. J AAPOS 22:102-106.e1
Zimmerman, Mark W; Liu, Yu; He, Shuning et al. (2018) MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov 8:320-335
Hammill, Jared T; Bhasin, Deepak; Scott, Daniel C et al. (2018) Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem 61:2694-2706
Li, Yanfeng; Bakke, Jesse; Finkelstein, David et al. (2018) HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 7:9
Khan, Raja B; Merchant, Thomas E; Sadighi, Zsila S et al. (2018) Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol 136:379-384
Ma, Xiaotu; Liu, Yu; Liu, Yanling et al. (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371-376
Broniscer, Alberto; Jia, Sujuan; Mandrell, Belinda et al. (2018) Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer 65:e27035

Showing the most recent 10 out of 6764 publications